Anti-Doping in Commercial Combat Sports: The Loophole Is the Collection Window, Not the Laboratory

On December 24, 2026, six days before fight night, UFC 232 was pulled out of Las Vegas and moved to The Forum in Inglewood, California. No fighter had been injured. No television rights dispute existed. The Nevada State Athletic Commission said it needed more time to review an arbitration ruling tied to one fighter's test result. The California State Athletic Commission issued the licence within hours. An event worth tens of millions of dollars changed states because the authority to rule on a case sat in two different places.

Four months earlier, that fighter's file had passed through three layers. A urine sample collected on July 28, 2026, on the day of the weigh-in for the following night's event. An adverse finding for the M3 metabolite of dehydrochloromethyltestosterone. An arbitration award concluding the compound originated in a contaminated dietary supplement. Three samples, two conclusions, one licence. That sequence was enough for me to keep the entire document set on a hard drive and reread it every time someone declares the doping problem in combat sports solved.

The arena was clean. The locker room was not. And more importantly, the collection schedule was not.

Context: a programme paid for by the ticket seller

From mid-2026 through December 31, 2026, the UFC ran an independent anti-doping programme with the United States Anti-Doping Agency (USADA). It was the first time a major commercial combat sports organisation outsourced testing to an outside body with year-round out-of-competition collection authority. From January 1, 2026, the contract moved to Drug Free Sport International. The financial architecture did not change: the testing money still flows from the promoter.

That is the line worth underlining in red. An anti-doping programme has three separate components: who pays, who collects, and who adjudicates. The laboratory does not know the athlete's name. That is why I trust the laboratories. But the payer knows each fighter's competition calendar, knows who is being pushed as the next box-office draw, and knows which week of the year a positive result does the least damage to revenue. The authority to set the testing budget is never separate from the authority to set the fight schedule.

In boxing the picture is more fragmented. The World Boxing Council launched its Clean Boxing Program in 2026 working with the Voluntary Anti-Doping Association (VADA), but its scope attaches to championship belts and to individual bout contracts. Other sanctioning bodies run their own mechanisms, with their own standards and their own publication timing. ONE Championship took a different route: hydration testing, a urine specific gravity threshold before weigh-in, and a ban on cutting water to make weight. For wushu and sanda, the International Wushu Federation is a signatory to the World Anti-Doping Code, but at multi-sport games the collection is coordinated by the organising committee through WADA-accredited laboratories.

Three models, three philosophies. None of them failed for lack of analytical equipment.

Core: the collection window is the only variable the fighter controls

Anti-doping operates in two windows. The in-competition window typically runs from roughly twelve hours before the weigh-in until after the bout ends. The out-of-competition window is the rest of the year, and that is where everything is decided.

A professional fighter competing three times a year spends about ten weeks in camp and about thirty weeks outside it. During those thirty weeks, collection depends on the promoter's budget, on the athlete's travel schedule, and on the accuracy of the whereabouts filing system. Three filing failures in twelve months constitute an anti-doping rule violation, even with no adverse sample. That is the strongest clause in the entire framework, and it is also the clause that rests most heavily on an administrative act: an entry typed into a phone application.

The detection mechanism of a substance determines the whole strategy. Dehydrochloromethyltestosterone leaves behind the M3 metabolite, which persists in urine for months after use. That is precisely why the July 28, 2026 sample broke the case open, and precisely why a compound like that is rarely chosen by anyone doing arithmetic. Testosterone suspension, short-acting EPO analogues and growth hormone, by contrast, have half-lives measured in hours or a few days. For that group, testing on weigh-in day is close to meaningless. Catching them requires a blood draw at six in the morning, in the fourth week of camp, when the fighter has no bout scheduled for ten weeks.

The number that regulators should publish is the count of out-of-competition collections in the ninety days before a new contract is signed. Not the annual total. The density of testing in the period when the fighter has nothing to lose.

Contracts usually run to one page. Dirty contracts come with an appendix. In fight agreements I have read through document files, the anti-doping compliance obligation sits in the appendix and the penalty clause sits on the main page. That separation is not accidental: it lets one side invoke the obligation while the other negotiates the price.

The economics explain most of the behaviour. A single urine collection plus analysis costs a few hundred dollars; a blood sample for the athlete biological passport costs more. For an organisation with hundreds of contracted fighters, the annual bill reaches into the millions. That is a business decision, not a scientific one. And when the fine is smaller than the purse, which way that decision leans is calculable.

In June 2026, an out-of-competition sample returned an adverse finding for clomiphene ahead of UFC 200. The bout result was later changed to a no contest on December 15, 2026, alongside a two hundred and fifty thousand dollar fine. That sum was smaller than the fighter's own disclosed purse for that night. A penalty cheaper than the cost of the violation stops being a penalty and becomes a fee.

The opposite side exists and deserves full weight. Many adverse findings originate in cross-contaminated dietary supplements, in a manufacturing market that is barely regulated in many countries. In 2026, a Cuban middleweight tested positive and was subsequently found to bear no fault because the source was a supplement. That case demonstrates that the price of a false result is a career. Any system that optimises only for the number of catches and not for accuracy will produce both error types: missing the guilty and destroying the innocent.

Contrarian: more testing does not equal more deterrence

The popular argument holds that increasing collection frequency will clean the sport. The data does not support that simple claim. Sample distribution across athletes is heavily skewed: some are called eight to ten times a year, others never. A programme with a high total and a skewed distribution produces the sensation of deterrence while the actual density in the high-risk group stays low.

In the other direction, collection at very high frequency also has scientific limits. The athlete biological passport works by tracking trends, not by comparing against a fixed threshold. Concluding that a profile is abnormal requires many data points over a long period, plus carbon isotope ratio testing to distinguish endogenous testosterone from exogenous testosterone. A single sample is almost never sufficient.

Therapeutic use exemptions are the most opaque document class in the entire system, and that does not automatically make them wrong. Many fighters have genuine conditions and need genuine medication. The problem is that the public cannot see the documents, cannot see validity periods, cannot see approval criteria. A system that demands absolute trust while refusing to publish its procedure cannot blame fans for suspicion.

And there is an uncomfortable fact: most criticism aimed at strict anti-doping programmes comes from parties with a commercial interest in a full roster. That does not make the criticism wrong. It only means the motive should be examined independently of the argument.

Based on my experience following fights over many years, what changes fighter behaviour is not the number on a press release. It is the predictability of being called. A careful fighter schedules substance use around the probability of collection. When that probability becomes genuinely random, the cost of the calculation spikes, and that is when deterrence starts working.

Takeaway

Three questions belong in front of any anti-doping announcement in combat sports. Who pays for the collection. Who controls when results are published. And how many out-of-competition collections occurred in the ninety days before a fighter signed a new contract.

The integrity index of a sport is not the number of positive tests announced. It is the number of times a fighter was caught while expecting nothing. Until the testing money is separated from the ticket money, the collection window remains a negotiable variable.